arXiv:2603.21743v4 Announce Type: replace Abstract: Building virtual cells with generative models to simulate cellular behavior in silico is emerging as a promising paradigm for accelerating drug discovery. However, prior image-based generative approaches can produce implausible cell images that violate basic physical and biological constraints. To address this, we propose to post-train virtual cell models with reinforcement learning (RL), leveraging biologically meaningful evaluators as reward functions. We design seven rewards spanning three categories-biological function, structural validit
The convergence of advanced generative AI models and the increasing sophistication of reinforcement learning algorithms enables this novel approach to 'post-train' virtual cell models for biological accuracy.
This development represents a significant step towards more reliable in silico biological simulations, directly addressing a key limitation in current generative AI applications for scientific discovery.
Virtual cell models can now be fine-tuned to adhere to fundamental biological constraints, moving beyond purely image-based generation towards more functional and valid representations for drug discovery.
- · Pharmaceutical companies
- · Biotechnology research
- · AI algorithm developers
- · Computational biology
- · Traditional drug screening methods
- · Untrained generative AI models in biology
More accurate and efficient drug discovery processes will emerge from reliable virtual cell models.
The ability to simulate complex biological interactions reliably could accelerate the development of personalized medicine.
This precision in biological modeling might lead to the engineered synthesis of novel biological entities with targeted functionalities.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG